Abstract
Background Carriers of the E40K loss-of-function variant in Angiopoietin-like 4 (ANGPTL4), have lower plasma triglyceride levels as well as lower rates of coronary artery disease (CAD) and type 2 diabetes (T2D). These genetic data suggest ANGPTL4 inhibition as a potential therapeutic target for cardiometabolic diseases. However, it is unknown whether the association between E40K and human diseases is due to linkage disequilibrium confounding. The broader impact of genetic ANGPTL4 inhibition is also unknown, raising uncertainties about the safety and validity of this target.
Methods To assess the impact of ANGPLT4 inhibition, we evaluated the impact of E40K and other loss-of-function variants in ANGPTL4 on a wide range of health markers and diseases.. The E40K impact was assessed in 29 publicly available genome-wide association meta-analyses of European ancestry on cardiometabolic traits and diseases as well as 1589 diseases assessed in electronic health record within FinnGen (n=309,154). To ensure that these relationships were truly causal, and not driven by other correlated variants, we used the Bayesian fine mapping algorithm CoPheScan.
Results The CoPheScan posterior probability of E40K being the causal variant for triglyceride was 99.99%, validating the E40K to proxy lifelong lower activity of ANGPTL4. The E40K mutation was associated with lower risk of CAD (odds ratio [OR]=0.84, 95% CI=0.81 to 0.87, p=3.6e-21) and T2D (OR=0.91, 95% CI=0.87 to 0.95, p=2.8e-05) in GWAS meta-analyses, with results replicated in FinnGen. These significant results were also replicated using other rarer loss-of-function variants identified through whole exome sequencing in 488,278 participants of various ancestry in the UK Biobank. Using a Mendelian randomization study design, the E40K variant effect on cardiometabolic diseases was concordant with lipoprotein lipase enhancement (r=0.85), but not hepatic lipaseenhancement (r=-0.10), suggesting that ANGPTL4 effects on cardiometabolic diseases are potentially mainly mediated through lipoprotein lipase. The E40K variant did not significantly increase the risk of any of the 1589 diseases tested in FinnGen.
Conclusion ANGPTL4 inhibition may represent a potentially safe and effective target for cardiometabolic diseases prevention or treatment.
Competing Interest Statement
BJA is a consultant for Novartis, Eli Lilly, Editas Medicine and Silence Therapeutics and has received research contracts from Pfizer, Eli Lilly and Silence Therapeutics.
Funding Statement
EGagnon holds a doctoral research award from the Fonds de recherche du Quebec: Sante. (FRQS). JB holds a masters research award from the FRQS. EGob holds a Doctoral Research Award from the Canadian Institutes of Health Research. BJA holds a senior scholar awards from the FRQS.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data used in this study are in the public domain. Supplementary Table 1 describes the data used and relevant information to retrieve the summary statistics.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data used in this study are in the public domain. Supplementary Table 1 describes the data used and relevant information to retrieve the summary statistics.
